Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing

Gespeichert in:
Bibliographische Detailangaben
Weitere Verfasser: Dolton, Michael J. (BerichterstatterIn) , Mikus, Gerd (BerichterstatterIn) , Weiß, Johanna (BerichterstatterIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2014
In: The journal of antimicrobial chemotherapy
Year: 2014, Jahrgang: 69, Heft: 6, Pages: 1633-1641
ISSN:1460-2091
DOI:10.1093/jac/dku031
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1093/jac/dku031
Volltext
Verfasserangaben:Michael J. Dolton, Gerd Mikus, Johanna Weiss, John E. Ray and Andrew J. McLachlan

MARC

LEADER 00000caa a2200000 c 4500
001 1521589151
003 DE-627
005 20220812102155.0
007 cr uuu---uuuuu
008 151110s2014 xx |||||o 00| ||eng c
024 7 |a 10.1093/jac/dku031  |2 doi 
035 |a (DE-627)1521589151 
035 |a (DE-576)451589157 
035 |a (DE-599)BSZ451589157 
035 |a (OCoLC)1340717596 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a 33  |2 sdnb 
245 0 0 |a Understanding variability with voriconazole using a population pharmacokinetic approach  |b implications for optimal dosing  |c Michael J. Dolton, Gerd Mikus, Johanna Weiss, John E. Ray and Andrew J. McLachlan 
264 1 |c 2014 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.11.2015 
700 1 |a Dolton, Michael J.  |0 (DE-588)1078652147  |0 (DE-627)839018541  |0 (DE-576)451589289  |4 oth 
700 1 |a Mikus, Gerd  |0 (DE-588)110903137  |0 (DE-627)691097941  |0 (DE-576)336988710  |4 oth 
700 1 |a Weiß, Johanna  |0 (DE-588)1050230906  |0 (DE-627)783666322  |0 (DE-576)404441114  |4 oth 
773 0 8 |i In  |t The journal of antimicrobial chemotherapy  |d Oxford : Oxford Univ. Press, 1975  |g 69(2014), 6, Seite 1633-1641  |h Online-Ressource  |w (DE-627)266876838  |w (DE-600)1467478-6  |w (DE-576)075144972  |x 1460-2091  |7 nnas  |a Understanding variability with voriconazole using a population pharmacokinetic approach implications for optimal dosing 
773 1 8 |g volume:69  |g year:2014  |g number:6  |g pages:1633-1641  |g extent:9  |a Understanding variability with voriconazole using a population pharmacokinetic approach implications for optimal dosing 
856 4 0 |u http://dx.doi.org/10.1093/jac/dku031  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20151110 
993 |a Article 
994 |a 2014 
998 |g 1050230906  |a Weiß, Johanna  |m 1050230906:Weiß, Johanna  |d 910000  |d 910100  |e 910000PW1050230906  |e 910100PW1050230906  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 110903137  |a Mikus, Gerd  |m 110903137:Mikus, Gerd  |d 910000  |d 910100  |e 910000PM110903137  |e 910100PM110903137  |k 0/910000/  |k 1/910000/910100/  |p 2 
999 |a KXP-PPN1521589151  |e 2871803188 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1521589151","language":["eng"],"note":["Gesehen am 10.11.2015"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Understanding variability with voriconazole using a population pharmacokinetic approach","subtitle":"implications for optimal dosing","title_sort":"Understanding variability with voriconazole using a population pharmacokinetic approach"}],"person":[{"given":"Michael J.","family":"Dolton","role":"oth","display":"Dolton, Michael J."},{"role":"oth","display":"Mikus, Gerd","given":"Gerd","family":"Mikus"},{"given":"Johanna","family":"Weiß","role":"oth","display":"Weiß, Johanna"}],"relHost":[{"pubHistory":["1.1975 -"],"titleAlt":[{"title":"JAC"}],"part":{"volume":"69","text":"69(2014), 6, Seite 1633-1641","extent":"9","year":"2014","pages":"1633-1641","issue":"6"},"note":["Gesehen am 27.10.21"],"disp":"Understanding variability with voriconazole using a population pharmacokinetic approach implications for optimal dosingThe journal of antimicrobial chemotherapy","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"266876838","language":["eng"],"title":[{"title_sort":"journal of antimicrobial chemotherapy","title":"The journal of antimicrobial chemotherapy","subtitle":"JAC"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Oxford","dateIssuedDisp":"1975-","publisher":"Oxford Univ. Press","dateIssuedKey":"1975"}],"id":{"issn":["1460-2091"],"eki":["266876838"],"zdb":["1467478-6"]},"name":{"displayForm":["the British Society for Antimicrobial Chemotherapy"]}}],"physDesc":[{"extent":"9 S."}],"id":{"doi":["10.1093/jac/dku031"],"eki":["1521589151"]},"origin":[{"dateIssuedDisp":"2014","dateIssuedKey":"2014"}],"name":{"displayForm":["Michael J. Dolton, Gerd Mikus, Johanna Weiss, John E. Ray and Andrew J. McLachlan"]}} 
SRT |a UNDERSTAND2014